Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market
As Accord Announces Withdrawal Of MAA
Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.
